Buprenorphine
- Generic Name
- Buprenorphine
- Brand Names
- Belbuca, Brixadi, Buprenex, Buprenorphine, Butrans, Sublocade, Suboxone, Subutex, Zubsolv, Buvidal, Sixmo
- Drug Type
- Small Molecule
- Chemical Formula
- C29H41NO4
- CAS Number
- 52485-79-7
- Unique Ingredient Identifier
- 40D3SCR4GZ
- Background
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain. It is also commonly used as an alternative to methadone for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose c...
- Indication
Buprenorphine is available in different formulations, such as sublingual tablets, buccal films, transdermal films, and injections, alone or in combination with naloxone.
...
- Associated Conditions
- Opioid Dependence, Severe Pain, Moderate Opioid Dependence, Moderate Pain, Severe Opioid Dependence
- Associated Therapies
- -
INDV-6001 Multiple-Dose Pharmacokinetic Study
- Conditions
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Indivior Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT06576843
- Locations
- 🇺🇸
Chicago Clinical Research Institute Inc., Chicago, Illinois, United States
🇺🇸Artemis Institute for Clinical Research, San Diego, California, United States
🇺🇸Innovative Clinical Research, Inc., Miami Lakes, Florida, United States
Standard Versus High Dose ED-Initiated Buprenorphine Induction
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Yale University
- Target Recruit Count
- 360
- Registration Number
- NCT06494904
- Locations
- 🇺🇸
Highland Hospital, Oakland, California, United States
🇺🇸San Leandro Hospital, San Leandro, California, United States
🇺🇸University of Utah Hospital, Salt Lake City, Utah, United States
Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT06406400
- Locations
- 🇺🇸
Research Site, Baltimore, Maryland, United States
Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD with Fentanyl Use
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 60
- Registration Number
- NCT06379984
- Locations
- 🇺🇸
University of Pennsylvania Center for Studies of Addiction, Philadelphia, Pennsylvania, United States
Identifying Optimal Buprenorphine Dosing for Opioid Use Disorder Treatment and Prevention of Overdose
- First Posted Date
- 2024-03-18
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Rhode Island Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT06316830
Psychopharmacological Treatment of Emotional Distress
- Conditions
- Interventions
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 80
- Registration Number
- NCT06133114
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Oral Buprenorphine as a Novel Low-dose Induction Strategy for Opioid Use Disorder
- First Posted Date
- 2023-10-17
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06086275
- Locations
- 🇺🇸
Brigham and Women's hospital, Boston, Massachusetts, United States
Maternal Brain Imaging in Opioid Use Disorder
- First Posted Date
- 2023-08-24
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 40
- Registration Number
- NCT06008990
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
Extended-release Pharmacotherapy for Opioid Use Disorder
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- King's College London
- Target Recruit Count
- 342
- Registration Number
- NCT05164549
- Locations
- 🇬🇧
South London and Maudsley NHS Foundation Trust, London, United Kingdom
🇬🇧NHS Tayside, Dundee, United Kingdom
🇬🇧Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom
Opioid Use Disorder Treatment Linkage at Sexual Health Clinics Using Buprenorphine
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2023-03-23
- Lead Sponsor
- Friends Research Institute, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT04991974
- Locations
- 🇺🇸
Baltimore City Health Department Sexual Health Clinics, Baltimore, Maryland, United States
🇺🇸Friends Research Institute, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.